Orthofix: Q1 Earnings Snapshot
LEWISVILLE, Texas (AP) — LEWISVILLE, Texas (AP) — Orthofix Medical Inc. (OFIX) on Tuesday reported a loss of $53.1 million in its first quarter.
On a per-share basis, the Lewisville, Texas-based company said it had a loss of $1.35. Losses, adjusted for non-recurring costs and stock option expense, were 8 cents per share.
The medical device maker posted revenue of $193.6 million in the period.
Orthofix expects full-year revenue in the range of $808 million to $816 million.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
New Zealand Rugby CEO Mark Robinson to step down at year's end
WELLINGTON, New Zealand (AP) — New Zealand Rugby chief executive Mark Robinson will step down at the end of the year, creating a vacancy in one of the most powerful jobs in New Zealand sport. Robinson led New Zealand's national sport for six years, through the difficult period of the pandemic when matches often took place in empty stadiums. He also has guided the sport's national governing body through difficult financial times. New Zealand Rugby has reported substantial deficits in each of the last three years. Along with many national rugby unions, New Zealand has faced increasing costs in retaining top players. The almost 20 million New Zealand dollar deficit ($10.2 million) posted by NZR in the last financial year came despite record revenues, reflecting the increasing difficulty national rugy administrators face in making ends meet. Robinson oversaw the deal in which investment company Silver Lake paid more than 200 million dollars ($120 million) for a share of NZR's commercial revenues. The deal at first was opposed by the professional players' union but later allowed NZR to financially support provincial rugby unions after the pandemic. Robinson also was party to the decision to appoint Scott Robertson as All Blacks head coach months before Ian Foster's tenure finished. Foster led the All Blacks to the final of the 2023 World Cup in which they lost by one point to South Africa. Robinson on Monday said he's leaving to join his wife and family who have relocated to Australia. "The past six years have been a period of rapid change or unprecedented challenges through the pandemic and significant evolution across commercial, competitions and structures,' Robinson said in a statement. 'I will reflect on that as I get closer to stepping away but I firmly believe the foundations of our organization are extremely strong and the game is well-placed for the future.' Robinson succeeded Steve Tew as chief executive in 2019. He will leave prior to a reorganization which will see the incoming chief executive take charge of both New Zealand Rugby and New Zealand Rugby Commercial, the sporting and commercial parts of the game. ___
Fox Sports
an hour ago
- Fox Sports
New Zealand Rugby CEO Mark Robinson to step down at year's end
Associated Press WELLINGTON, New Zealand (AP) — New Zealand Rugby chief executive Mark Robinson will step down at the end of the year, creating a vacancy in one of the most powerful jobs in New Zealand sport. Robinson led New Zealand's national sport for six years, through the difficult period of the pandemic when matches often took place in empty stadiums. He also has guided the sport's national governing body through difficult financial times. New Zealand Rugby has reported substantial deficits in each of the last three years. Along with many national rugby unions, New Zealand has faced increasing costs in retaining top players. The almost 20 million New Zealand dollar deficit ($10.2 million) posted by NZR in the last financial year came despite record revenues, reflecting the increasing difficulty national rugy administrators face in making ends meet. Robinson oversaw the deal in which investment company Silver Lake paid more than 200 million dollars ($120 million) for a share of NZR's commercial revenues. The deal at first was opposed by the professional players' union but later allowed NZR to financially support provincial rugby unions after the pandemic. Robinson also was party to the decision to appoint Scott Robertson as All Blacks head coach months before Ian Foster's tenure finished. Foster led the All Blacks to the final of the 2023 World Cup in which they lost by one point to South Africa. Robinson on Monday said he's leaving to join his wife and family who have relocated to Australia. "The past six years have been a period of rapid change or unprecedented challenges through the pandemic and significant evolution across commercial, competitions and structures,' Robinson said in a statement. 'I will reflect on that as I get closer to stepping away but I firmly believe the foundations of our organization are extremely strong and the game is well-placed for the future.' Robinson succeeded Steve Tew as chief executive in 2019. He will leave prior to a reorganization which will see the incoming chief executive take charge of both New Zealand Rugby and New Zealand Rugby Commercial, the sporting and commercial parts of the game. ___ AP rugby:
Yahoo
2 hours ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
